Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).

@article{Meja2017InterstitialLD,
  title={Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF).},
  author={Mayra Edith Mej{\'i}a and Denisse Herrera-Bringas and Diana I P{\'e}rez-Rom{\'a}n and Hermes Rivero and Heidegger Mateos-Toledo and Pedro Castorena-Garc{\'i}a and Jos{\'e} E. Figueroa and Jorge Rojas-Serrano},
  journal={Respiratory medicine},
  year={2017},
  volume={123},
  pages={79-86}
}
OBJECTIVE to describe the clinical manifestations and survival of patients with ILD and myositis-specific and associated autoantibodies, and to evaluate the performance of the new ATS/ERS classification criteria for IPAF. PATIENTS AND METHODS Patients with ILD and positive in at least one of the following autoantibodies: anti-Jo-1, anti-Ej, anti-PL7, anti… CONTINUE READING